34 results about "Glioma cell lines" patented technology

The invention provides miR-124-containing glioma cell exosomes, a preparation method and application thereof, and belongs to the technical field of central nervous system damage repairing drugs. A method for preparing glioma cell exosomes containing miR-124, the supernatant obtained by culturing a glioma cell line is subjected to solid-liquid separation; the separated exosomes and miR-124 are mixed and incubated together to obtain a Glioma cell exosomes of miR‑124. The exosomes prepared above can effectively bind to cholesterol-modified miR-124 and be absorbed by reactive astrocytes, significantly increase the expression of miR-124 in reactive astrocytes, and inhibit astrocytes. Activation and scarring. Therefore, the present invention also provides the application of miR-124-containing glioma cell exosomes in the preparation of a drug for inhibiting astrocyte activation and / or glial scar formation, thereby treating central nervous system injury diseases.

The invention discloses the application of a crRNA-mediated CRISPR / Cas13a gene editing system in tumor cells. In the U87 glioma cell line, the Cas13a protein of the present invention can be mediated by a single-stranded crRNA to a complementary target RNA and cut. At the same time, Cas13a protein can also trigger the effect of joint shearing in eukaryotic cells, that is, after starting to cut the first entry of RNA, Cas13a protein will randomly cut other RNAs encountered without purpose, thereby reducing Tumor cell index, inhibition of tumor formation rate and tumor size in mice and other effects of inhibiting and killing tumors. The invention provides a new method for inhibiting or killing tumor cells, and lays the foundation for the application of the random shearing effect of the CRISPR-Cas13 system in eukaryotic cells.

The present invention provides a TOP2A inhibition by temozolomide useful for predicting glioblastoma patient's survival. Glioblastoma (GBM) is the most common, malignant primary adult brain tumor. The conventional treatments for GBM, include surgery, radiation, and chemotherapy which have only modestly improved patient survival. The patients with GBM expressing higher TOP2A transcript levels had better prognosis. More interestingly, the present invention reports that temozolomide is an inhibitor of TOP2A activity in vitro. The present invention further shows that siRNA knock down of TOP2A rendered a glioma cell line resistant to temozolomide chemotherapy. Thus it is demonstrated for the first time that temozolomide is a TOP2A inhibitor and establishes that TOP2A transcript levels determines the chemosensitivity of glioblastoma to temozolomide therapy thus explaining the very high levels of TOP2A transcript being a good prognostic indicator in GBM patients receiving temozolomide chemotherapy.

The invention discloses a bridge molecule 1-siRNA interference sequence and a fusion expression vector thereof, and belongs to the technical field of biology. A fragment of synthesized bridge molecule1-siRNA interference sequence can reduce the expression of bridge molecule 1 protein, and generate inhibiting effect on cellular infiltration and diffusion function participated by the bridge molecule 1 protein; and after transfecting a human glioma cell line, the bridge molecule 1-siRNA fusion expression vector can specifically degrade bridge molecules 1mRNA complemented with the fusion expression vector, inhibit in vitro migration capability and chemotactic capability of malignant glioma LN-229 cells, inhibit in vitro adhesive capability and invasion capability of the malignant glioma LN-229 cells, reduce infiltration and diffusion capabilities of tumor cells, and provide a feasible technological measure for gene therapy of tumor.

The invention discloses a cytoskeletal binding protein siRNA (small interfering ribonucleic acid) interfering sequence, a fusion expression vector thereof and medical application of the same, belonging to the field of biological pharmacy. The invention designs a segment of cytoskeletal binding protein siRNA interfering sequence, and synthesizes the fusion expression vector of the cytoskeletal binding protein siRNA interfering sequence; after the fusion expression vector is transfected into a human glioma cell line, the fusion expression vector can specifically degrade the cytoskeletal binding protein messenger RNA (mRNA) complementary to the fusion expression vector to reduce the expression of the cytoskeletal binding protein in the human glioma cells; and the fusion expression vector can effectively inhibit the migration, adhesion and invasion abilities of the human glioma cells, has an effect on inhibiting the human glioma cellular infiltration and metastasis, and provides a feasible technical means for gene therapy for tumor patients.